Enanta Pharmaceuticals reported $201K in Ordinary Share Capital for its fourth fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ordinary Share Capital Change
Amgen AMGN:US $ 31806M 4M
Anika Therapeutics ANIK:US $ 0.14M 0M
Arrowhead Research ARWR:US $ 196K 1000
AstraZeneca AZN:LN 328M 0M
Biocryst Pharmaceuticals BCRX:US $ 1.78M 0.01M
Biogen BIIB:US $ 0.1M 0M
Bristol Myers Squibb BMY:US $ 292M 0M
Clovis Oncology CLVS:US $ 0.1M 0M
GlaxoSmithKline GSK:LN 1346M 0M
Halozyme Therapeutics HALO:US $ 0.14M 0.01M
Heron Therapeutics HRTX:US $ 0.91M 0M
Insmed INSM:US $ 1.03M 5K
Intercept Pharmaceuticals ICPT:US $ 0.03M 0M
Karyopharm Therapeutics KPTI:US $ 8K 1000
Neurocrine Biosciences NBIX:US $ 0.1M 0M
Novartis NOVN:VX SF 913M 0M
Novavax NVAX:US $ 0.74M 0.03M
Ptc Therapeutics PTCT:US $ 0.07M 0M
Sarepta Therapeutics SRPT:US $ 0.01M 0M
Vital Therapies VTL:US $ 0M 0M